Trade Mark Journal No.2026/005 30 January 2026
WO0000001896655 (5,42)
Office of origin: United States of America
Date of International Registration:12 November 2025
Date of designation in the UK:
12 November 2025
The mark consists of an abstract image of a bird made out of a circle, teardrops, and a square to the left of the word terns.
International priority date claimed: 8 August 2025
(United States of America)
(99328453)
- Class 5
- Pharmaceutical preparations, namely, small-molecule drugs for the treatment of cancer, metabolic disorders, and endocrine disorders; pharmaceutical and biologic preparations for use in the treatment of oncology-related diseases and disorders; pharmaceutical and biologic preparations for use in the treatment of metabolic-related diseases and disorders; pharmaceutical and biologic preparations for use in the treatment of endocrine-related diseases and disorders; pharmaceutical and biologic preparations for use in the treatment of diabetes and obesity-related diseases and disorders; peptides for pharmaceutical purposes, namely, for the treatment of cancer, metabolic disorders, and endocrine disorders.
- Class 42
- Pharmaceutical and biologic drug development services, namely, development of small-molecule drugs for use in humans; pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of oncology-related diseases and disorders; pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of metabolic-related diseases and disorders; pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of endocrine-related diseases and disorders; pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of diabetes and obesity-related diseases and disorders; research and development services in the field of pharmaceutical and biologic preparations; research and development services in the field of oncology-related diseases and disorders; research and development services in the field of metabolic-related diseases and disorders; research and development services in the field of endocrine-related diseases and disorders; research and development services in the fields of diabetes and obesity-related diseases and disorders; research and development services in the field of peptide pharmaceutical preparations; providing medical and scientific research information in the field of small-molecule drugs; providing medical and scientific research information in the field of clinical trials and post-market trials; providing medical and scientific research information in the field of oncology, metabolic, endocrine, diabetes, and obesity-related diseases and disorders.
Terns Pharmaceuticals, Inc.
Representative: Tiffany D. Gehrke Marshall, Gerstein & Borun LLP, 233 South Wacker Drive,, Suite 6300, Chicago IL 60606, UNITED STATES OF AMERICA